Attention Deficit Hyperactivity Disorder Market
SHARE
PUBLISHED: 2022 ID: SMRC22169
SHARE

Attention Deficit Hyperactivity Disorder Market Forecasts to 2028 - Global Analysis By medication (Stimulant, Non Stimulant and Other Medications), By Psychotherapy (Behaviour Therapy, Cognitive Behavioural Therapy and Other Psychotherapies), By Education Or Training (Social Skills Training, Parent Management Training and Other Education Or Trainings ), Distribution Channel and By Geography.

4.9 (74 reviews)
4.9 (74 reviews)
Published: 2022 ID: SMRC22169

This report covers the impact of COVID-19 on this global market
Loading...

Years Covered

2020-2028

Estimated Year Value (2022)

US $13.21 BN

Projected Year Value (2028)

US $18.95 BN

CAGR (2022 - 2028)

6.2%

Regions Covered

North America, Europe, Asia Pacific, South America, and Middle East & Africa

Countries Covered

US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa

Largest Market

Asia Pacific

Highest Growing Market

Europe

According to Stratistics MRC, the Global Attention Deficit Hyperactivity Disorder Market is accounted for $13.21 billion in 2022 and is expected to reach $18.95 billion by 2028 growing at a CAGR of 6.2% during the forecast period. Attention Deficit Hyperactivity Disorder is a chronic condition including attention difficulty, hyperactivity and impulsiveness. Attention deficit hyperactivity disorder often begins in childhood and can persist into adulthood. It may contribute to low self-esteem, troubled relationships and difficulty at school or work. Symptoms include limited attention and hyperactivity. There are many treatment options that works best can depend on the individual child and family.

According to the Centers for Diseases Control and Prevention, in September 2021, 8.8% of people have been diagnosed with attention deficit hyperactivity disorder at some point in their lives. Moreover, 13.6 million visits to doctors' offices were made with attention deficit disorder as the primary diagnosis. In addition, increasing spending on the treatment of attention deficit hyperactivity disorder in the United States with rising prescription rates is expected to boost the market.



Market Dynamics:

Driver:

Rise in the incidence of attention deficit hyperactivity disorder

The causes of attention deficit hyperactivity disorder are still unclear, although genetic presence is observed in many cases. The incidence of this disorder is rising at a higher rate, which drives the global attention deficit hyperactivity disorder therapeutics market, as there is no treatment for this disorder. Moreover, increasing attentiveness regarding the syndrome among physicians and patients and opinion-based due to the lack of regular diagnostic tests and, increasing advancements in the medical field, a growing number of researches in neurosciences, and raising awareness about mental illness among people are encouraging the market growth to a significant level.

Restraint:

Involving side effects

Attention deficit hyperactivity disorder medication has side effects such as loss of appetite and trouble sleeping. Other attention deficit hyperactivity disorder medicine side effects include nervousness, irritability, moodiness, headaches, stomachaches, fast heart rate, and high blood pressure. Side effects usually happen in the first few days of starting a new medicine or taking a higher dose these side effects can also be controlled by reducing the dose or changing the medication, due to which patients are not convinced in adopting to the medication treatment thus hindering the market growth.

Opportunity:

Increasing prevalence of attention deficit hyperactivity disorder

Even though the prevalence of the attention deficit hyperactivity disorder is not known this disorder is highly prevalent in many children all around the world, hence there is a major need for the advancement in the medical field and innovated products for the treatment of attention deficit hyperactivity disorder in the market moreover the growth in responsiveness about mental illness amongst people are the factors expected to boost the growth of the attention-deficit hyperactivity disorder market in the forecast period.

Threat:

High cost of medication

The high cost of attention deficit hyperactivity disorder medications, improper reimbursement policies, and side effects related to the medications such as insomnia, anorexia, dizziness, headaches, and mood changes are restraining the growth of the global attention deficit hyperactivity disorder therapeutics market. Moreover, all the side effects connected with the drugs affect the patients lives and hamper the revenue growth of the attention-deficit hyperactivity disorder therapeutics market in the given forecast period.

Covid-19 Impact

The Pandemic has had a lot of harmful impacts on people suffering from attention-deficit hyperactivity disorder. The major reason for the consequence is susceptibility, to the distress caused by the pandemic and physical distancing measures, owing to these factors, the patient can display increased behavioural problems. The increase in the issues will boost the sale of attention deficit hyperactivity disorder therapeutics, and the buying by consumers has finished the stock of the current batch of medicines and forced them to make a fresh batch. Moreover, hospital visits for non-essential medical conditions have been delayed, causing persons with attention deficit hyperactivity disorder to depend totally on drugs helping in boosting the market growth.

The Stimulant segment is expected to be the largest during the forecast period

The Stimulant segment is estimated to have a lucrative growth, due to its increased activity in the brain particularly in areas that play a part in controlling attention and behaviour. Various drugs such as Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, etc are used in the treatment of Attention Deficit Hyperactivity Disorder. Amphetamines and methylphenidate are common stimulant medications prescribed to children, adolescents, and adults with attention deficit hyperactivity disorder. They work quickly, and there is also a reduction in overall impulsivity and attention deficit hyperactivity disorder symptoms in two hours. The stimulants are the most effective treatment for attention deficit hyperactivity disorder patients to keep them calm and focused. Thus the effectiveness of the stimulant drug in the management of attention deficit hyperactivity disorder boosts the segment growth over the forecast period.

The Behaviour therapy segment is expected to have the highest CAGR during the forecast period

The Behaviour therapy segment is anticipated to witness the fastest CAGR growth during the forecast period, due to effective treatment for attention deficit hyperactivity disorder that can improve a child's behaviour, self-control, and self-esteem. It is most helpful in young children when it is delivered by parents and is a short-term, goal-oriented form of psychotherapy that aims to change negative patterns of thinking and reframe the way a patient feels about herself and her symptoms of attention deficit hyperactivity disorder. Additionally, children benefit in the long term as they can apply the techniques any time they need to handle with negative emotions. Hence all the above factors contribute in the market growth.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the displeased needs and large patient population, and even the ease of access of lower-cost drugs for attention deficit hyperactivity disorder treatment. In addition, factors such as high awareness among healthcare professionals about drugs available for treatment and the rise in disease prevalence, private organizations and the bigger funding from the population are responsible for the regional market's growth. Also, the accessibility of new treatments and technology affects the growing demand and encourages the growth of the regional attention deficit hyperactivity disorder therapeutics market.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the growing alertness about the mental health and the increasing of the incidences of attention-deficit or hyperactivity disorder. Moreover, due to the large number of drug prescriptions, written each year, the increased number of product launches, and the increased collaboration among players to improve market penetration and product development. Furthermore, the high ingestion of additives and preservatives, and the improvising of the coverage for treatment of the condition which in turn are anticipated to further propel the growth of the attention-deficit hyperactivity market in the region in the coming years.



Key players in the market

Some of the key players profiled in the Attention Deficit Hyperactivity Disorder Market include Noven Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Neos Therapeutics, Inc., Supernus Pharmaceuticals, Novartis AG, Johnson & Johnson, Lilly, Pfizer Inc., Alcobra Ltd., Neurosigma, Inc, Hisamitsu Pharmaceutical Co.,Inc , KemPharm, Inc., Curemark, LLC., Mallinckrodt, UCB S.A, Purdue Pharma L.P. Actavis.

Key Developments:

In Nov 2022, Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria. This novel combination also contains an optimized formulation of lumefantrine, which allows it to be given once daily versus the usual twice-daily administration. As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination.

In Oct 2022, Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy. Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of Europe, Canada, Australia and China, a Phase 2b investigational therapy for the treatment of celiac disease.

In Jun 2022, Novartis announces partnership with the American Society of Hematology to fight sickle cell disease in Sub-Saharan Africa. The partnership with ASH will not only deliver better tools to track a baby’s diagnosis, but also support greater knowledge on treatment and care, including through publications on research findings, professional education and dissemination to policy makers and other audiences.

Medications Covered:
• Stimulant
• Non Stimulant
• Other Medications

Psychotherapies Covered:
• Behaviour Therapy
• Cognitive Behavioural Therapy
• Family Therapy
• Interpersonal Psychotherapy
• Other Psychotherapies

Education Or Trainings Covered:
• Social Skills Training
• Parent Management Training
• School-Based Interventions
• Other Education Or Trainings

Distribution Channels Covered:
• Retail Pharmacy
• Hospital Pharmacy
• Specialty Clinics
• E-Commerce
• Other Distribution Channels

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Attention Deficit Hyperactivity Disorder Market, By Medication
5.1 Introduction
5.2 Stimulant
5.2.1 Amphetamine
5.2.2 Dexmethylphenidate
5.2.3 Methylphenidate
5.2.4 Methylphenidate
5.2.5 Lisdexamfetamine dimesylate
5.3 Non Stimulant
5.3.1 Atomoxetine
5.3.2 Guanfacine
5.3.3 Atomoxetine
5.3.4 Clonidine
5.4 Other Medications

6 Global Attention Deficit Hyperactivity Disorder Market, By Psychotherapy
6.1 Introduction
6.2 Behaviour Therapy
6.3 Cognitive Behavioural Therapy
6.4 Family Therapy
6.5 Interpersonal Psychotherapy
6.6 Other Psychotherapies

7 Global Attention Deficit Hyperactivity Disorder Market, By Education Or Training
7.1 Introduction
7.2 Social Skills Training
7.3 Parent Management Training
7.4 School-Based Interventions
7.5 Other Education Or Trainings

8 Global Attention Deficit Hyperactivity Disorder Market, By Distribution Channel
8.1 Introduction
8.2 Retail Pharmacy
8.3 Hospital Pharmacy
8.4 Specialty Clinics
8.5 E-Commerce
8.6 Other Distribution Channel

9 Global Attention Deficit Hyperactivity Disorder Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa

10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling
11.1 Noven Pharmaceuticals, Inc.
11.2 Takeda Pharmaceutical Company Limited
11.3 Neos Therapeutics, Inc.
11.4 Supernus Pharmaceuticals
11.5 Novartis AG
11.6 Johnson & Johnson
11.7 Lilly, Pfizer Inc.
11.8 Alcobra Ltd.
11.9 Neurosigma, Inc
11.10 Hisamitsu Pharmaceutical Co.,Inc
11.11 KemPharm, Inc.
11.12 Curemark, LLC.
11.13 Mallinckrodt, UCB S.A.
11.14 Purdue Pharma L.P.
11.15 Actavis

List of Tables
1 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Region (2020-2028) ($MN)
2 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Medication (2020-2028) ($MN)
3 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
4 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Stimulant (2020-2028) ($MN)
5 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Amphetamine (2020-2028) ($MN)
6 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Dexmethylphenidate (2020-2028) ($MN)
7 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
8 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
9 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Lisdexamfetamine dimesylate (2020-2028) ($MN)
10 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Non Stimulant (2020-2028) ($MN)
11 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
12 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Guanfacine (2020-2028) ($MN)
13 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
14 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Clonidine (2020-2028) ($MN)
15 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Other Medications (2020-2028) ($MN)
16 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Psychotherapy (2020-2028) ($MN)
17 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
18 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Behaviour Therapy (2020-2028) ($MN)
19 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Cognitive Behavioral Therapy (2020-2028) ($MN)
20 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Family Therapy (2020-2028) ($MN)
21 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Interpersonal Psychotherapy (2020-2028) ($MN)
22 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Other Psychotherapies (2020-2028) ($MN)
23 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Education Or Training (2020-2028) ($MN)
24 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
25 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Social Skills Training (2020-2028) ($MN)
26 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Parent Management Training (2020-2028) ($MN)
27 Global Attention Deficit Hyperactivity Disorder Market Outlook, By School-Based Interventions (2020-2028) ($MN)
28 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Other Education Or Trainings (2020-2028) ($MN)
29 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Distribution Channel (2020-2028) ($MN)
30 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
31 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
32 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
33 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Specialty Clinics (2020-2028) ($MN)
34 Global Attention Deficit Hyperactivity Disorder Market Outlook, By E-Commerce (2020-2028) ($MN)
35 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Other Distribution Channel (2020-2028) ($MN)
36 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Country (2020-2028) ($MN)
37 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Medication (2020-2028) ($MN)
38 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
39 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Stimulant (2020-2028) ($MN)
40 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Amphetamine (2020-2028) ($MN)
41 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Dexmethylphenidate (2020-2028) ($MN)
42 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
43 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
44 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Lisdexamfetamine dimesylate (2020-2028) ($MN)
45 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Non Stimulant (2020-2028) ($MN)
46 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
47 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Guanfacine (2020-2028) ($MN)
48 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
49 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Clonidine (2020-2028) ($MN)
50 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Medications (2020-2028) ($MN)
51 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Psychotherapy (2020-2028) ($MN)
52 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
53 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Behaviour Therapy (2020-2028) ($MN)
54 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Cognitive Behavioral Therapy (2020-2028) ($MN)
55 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Family Therapy (2020-2028) ($MN)
56 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Interpersonal Psychotherapy (2020-2028) ($MN)
57 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Psychotherapies (2020-2028) ($MN)
58 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Education Or Training (2020-2028) ($MN)
59 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
60 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Social Skills Training (2020-2028) ($MN)
61 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Parent Management Training (2020-2028) ($MN)
62 North America Attention Deficit Hyperactivity Disorder Market Outlook, By School-Based Interventions (2020-2028) ($MN)
63 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Education Or Trainings (2020-2028) ($MN)
64 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Distribution Channel (2020-2028) ($MN)
65 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
66 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
67 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
68 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Specialty Clinics (2020-2028) ($MN)
69 North America Attention Deficit Hyperactivity Disorder Market Outlook, By E-Commerce (2020-2028) ($MN)
70 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Distribution Channel (2020-2028) ($MN)
71 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Country (2020-2028) ($MN)
72 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Medication (2020-2028) ($MN)
73 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
74 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Stimulant (2020-2028) ($MN)
75 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Amphetamine (2020-2028) ($MN)
76 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Dexmethylphenidate (2020-2028) ($MN)
77 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
78 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
79 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Lisdexamfetamine dimesylate (2020-2028) ($MN)
80 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Non Stimulant (2020-2028) ($MN)
81 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
82 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Guanfacine (2020-2028) ($MN)
83 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
84 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Clonidine (2020-2028) ($MN)
85 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Other Medications (2020-2028) ($MN)
86 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Psychotherapy (2020-2028) ($MN)
87 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
88 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Behaviour Therapy (2020-2028) ($MN)
89 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Cognitive Behavioral Therapy (2020-2028) ($MN)
90 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Family Therapy (2020-2028) ($MN)
91 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Interpersonal Psychotherapy (2020-2028) ($MN)
92 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Other Psychotherapies (2020-2028) ($MN)
93 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Education Or Training (2020-2028) ($MN)
94 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
95 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Social Skills Training (2020-2028) ($MN)
96 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Parent Management Training (2020-2028) ($MN)
97 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By School-Based Interventions (2020-2028) ($MN)
98 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Other Education Or Trainings (2020-2028) ($MN)
99 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Distribution Channel (2020-2028) ($MN)
100 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
101 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
102 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
103 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Specialty Clinics (2020-2028) ($MN)
104 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By E-Commerce (2020-2028) ($MN)
105 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Other Distribution Channel (2020-2028) ($MN)
106 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Country (2020-2028) ($MN)
107 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Medication (2020-2028) ($MN)
108 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
109 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Stimulant (2020-2028) ($MN)
110 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Amphetamine (2020-2028) ($MN)
111 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Dexmethylphenidate (2020-2028) ($MN)
112 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
113 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
114 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Lisdexamfetamine dimesylate (2020-2028) ($MN)
115 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Non Stimulant (2020-2028) ($MN)
116 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
117 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Guanfacine (2020-2028) ($MN)
118 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
119 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Clonidine (2020-2028) ($MN)
120 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Other Medications (2020-2028) ($MN)
121 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Psychotherapy (2020-2028) ($MN)
122 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
123 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Behaviour Therapy (2020-2028) ($MN)
124 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Cognitive Behavioral Therapy (2020-2028) ($MN)
125 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Family Therapy (2020-2028) ($MN)
126 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Interpersonal Psychotherapy (2020-2028) ($MN)
127 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Other Psychotherapies (2020-2028) ($MN)
128 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Education Or Training (2020-2028) ($MN)
129 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
130 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Social Skills Training (2020-2028) ($MN)
131 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Parent Management Training (2020-2028) ($MN)
132 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By School-Based Interventions (2020-2028) ($MN)
133 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Other Education Or Trainings (2020-2028) ($MN)
134 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Distribution Channel (2020-2028) ($MN)
135 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
136 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
137 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
138 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Specialty Clinics (2020-2028) ($MN)
139 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By E-Commerce (2020-2028) ($MN)
140 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Other Distribution Channel (2020-2028) ($MN)
141 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Country (2020-2028) ($MN)
142 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Medication (2020-2028) ($MN)
143 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
144 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Stimulant (2020-2028) ($MN)
145 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Amphetamine (2020-2028) ($MN)
146 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Dexmethylphenidate (2020-2028) ($MN)
147 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
148 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
149 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Lisdexamfetamine dimesylate (2020-2028) ($MN)
150 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Non Stimulant (2020-2028) ($MN)
151 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
152 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Guanfacine (2020-2028) ($MN)
153 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
154 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Clonidine (2020-2028) ($MN)
155 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Medications (2020-2028) ($MN)
156 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Psychotherapy (2020-2028) ($MN)
157 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
158 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Behaviour Therapy (2020-2028) ($MN)
159 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Cognitive Behavioral Therapy (2020-2028) ($MN)
160 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Family Therapy (2020-2028) ($MN)
161 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Interpersonal Psychotherapy (2020-2028) ($MN)
162 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Psychotherapies (2020-2028) ($MN)
163 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Education Or Training (2020-2028) ($MN)
164 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
165 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Social Skills Training (2020-2028) ($MN)
166 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Parent Management Training (2020-2028) ($MN)
167 South America Attention Deficit Hyperactivity Disorder Market Outlook, By School-Based Interventions (2020-2028) ($MN)
168 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Education Or Trainings (2020-2028) ($MN)
169 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Distribution Channel (2020-2028) ($MN)
170 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
171 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
172 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
173 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Specialty Clinics (2020-2028) ($MN)
174 South America Attention Deficit Hyperactivity Disorder Market Outlook, By E-Commerce (2020-2028) ($MN)
175 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Distribution Channel (2020-2028) ($MN)
176 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Country (2020-2028) ($MN)
177 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Medication (2020-2028) ($MN)
178 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
179 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Stimulant (2020-2028) ($MN)
180 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Amphetamine (2020-2028) ($MN)
181 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Dexmethylphenidate (2020-2028) ($MN)
182 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
183 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
184 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Lisdexamfetamine dimesylate (2020-2028) ($MN)
185 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Non Stimulant (2020-2028) ($MN)
186 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
187 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Guanfacine (2020-2028) ($MN)
188 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
189 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Clonidine (2020-2028) ($MN)
190 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Other Medications (2020-2028) ($MN)
191 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Psychotherapy (2020-2028) ($MN)
192 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
193 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Behaviour Therapy (2020-2028) ($MN)
194 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Cognitive Behavioral Therapy (2020-2028) ($MN)
195 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Family Therapy (2020-2028) ($MN)
196 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Interpersonal Psychotherapy (2020-2028) ($MN)
197 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Other Psychotherapies (2020-2028) ($MN)
198 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Education Or Training (2020-2028) ($MN)
199 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
200 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Social Skills Training (2020-2028) ($MN)
201 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Parent Management Training (2020-2028) ($MN)
202 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By School-Based Interventions (2020-2028) ($MN)
203 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Other Education Or Trainings (2020-2028) ($MN)
204 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Distribution Channel (2020-2028) ($MN)
205 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
206 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
207 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
208 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Specialty Clinics (2020-2028) ($MN)
209 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By E-Commerce (2020-2028) ($MN)
210 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Other Distribution Channel (2020-2028) ($MN)

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials